Business Description
Voyager Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US92915B1061
Compare
Compare
Traded in other countries / regions
VYGR.USAVT6.GermanyVYGR.Mexico IPO Date
2015-11-11Description
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 7.9 | |||||
| Equity-to-Asset | 0.77 | |||||
| Debt-to-Equity | 0.14 | |||||
| Debt-to-EBITDA | -26.31 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | 2.73 | |||||
| Beneish M-Score | -2.03 | |||||
| WACC vs ROIC | ||||||
Growth Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 7 | |||||
| 3-Year EBITDA Growth Rate | 50.3 | |||||
| 3-Year EPS without NRI Growth Rate | 44.7 | |||||
| 3-Year Book Growth Rate | 9.1 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | -33.56 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 46.01 | |||||
| 9-Day RSI | 48.72 | |||||
| 14-Day RSI | 50.05 | |||||
| 6-1 Month Momentum % | -25.19 | |||||
| 12-1 Month Momentum % | -10.55 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 9.51 | |||||
| Quick Ratio | 9.51 | |||||
| Cash Ratio | 9.25 | |||||
| Days Sales Outstanding | 45.34 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -5.6 | |||||
| Shareholder Yield % | -32.22 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -4.63 | |||||
| Net Margin % | 6.28 | |||||
| FCF Margin % | -15.49 | |||||
| ROE % | 3.5 | |||||
| ROA % | 2.42 | |||||
| ROIC % | -6.55 | |||||
| 3-Year ROIIC % | 345.81 | |||||
| ROC (Joel Greenblatt) % | -14.82 | |||||
| ROCE % | -2.1 | |||||
| Years of Profitability over Past 10-Year | 2 |
GF Value Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 31.09 | |||||
| PE Ratio without NRI | 31.09 | |||||
| PS Ratio | 2.46 | |||||
| PB Ratio | 1.11 | |||||
| Price-to-Tangible-Book | 1.11 | |||||
| EV-to-EBIT | -9.16 | |||||
| EV-to-EBITDA | -34.15 | |||||
| EV-to-Forward-EBITDA | -0.56 | |||||
| EV-to-Revenue | 0.42 | |||||
| EV-to-Forward-Revenue | 0.79 | |||||
| EV-to-FCF | -2.74 | |||||
| Price-to-Projected-FCF | 3.72 | |||||
| Price-to-Graham-Number | 1.24 | |||||
| Price-to-Net-Current-Asset-Value | 1.33 | |||||
| Price-to-Net-Cash | 1.38 | |||||
| Earnings Yield (Greenblatt) % | -10.92 | |||||
| FCF Yield % | -5.97 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:VYGR
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Voyager Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 143.769 | ||
| EPS (TTM) ($) | 0.22 | ||
| Beta | 1.37 | ||
| Volatility % | 54.03 | ||
| 14-Day RSI | 50.05 | ||
| 14-Day ATR ($) | 0.473215 | ||
| 20-Day SMA ($) | 7.02225 | ||
| 12-1 Month Momentum % | -10.55 | ||
| 52-Week Range ($) | 5.71 - 11.72 | ||
| Shares Outstanding (Mil) | 54.53 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Voyager Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Voyager Therapeutics Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Voyager Therapeutics Inc Frequently Asked Questions
What is Voyager Therapeutics Inc(VYGR)'s stock price today?
The current price of VYGR is $6.85. The 52 week high of VYGR is $11.72 and 52 week low is $5.71.
When is next earnings date of Voyager Therapeutics Inc(VYGR)?
The next earnings date of Voyager Therapeutics Inc(VYGR) is .
Does Voyager Therapeutics Inc(VYGR) pay dividends? If so, how much?
Voyager Therapeutics Inc(VYGR) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers